Older adults mount less durable humoral responses to two doses of COVID-19 mRNA vaccine but strong initial responses to a third dose
F Mwimanzi, HR Lapointe, PK Cheung… - The Journal of …, 2022 - academic.oup.com
Background Third coronavirus disease 2019 (COVID-19) vaccine doses are broadly
recommended, but immunogenicity data remain limited, particularly in older adults. Methods …
recommended, but immunogenicity data remain limited, particularly in older adults. Methods …
Significant reduction in humoral Immunity among healthcare workers and nursing home residents 6 months AFTER COVID-19 BNT162b2 mRNA vaccination
DH Canaday, OA Oyebanji, D Keresztesy, M Payne… - MedRxiv, 2021 - medrxiv.org
High COVID-19 mortality among nursing home (NH) residents led to their prioritization for
SARS-CoV-2 vaccination; most NH residents received BNT162b2 mRNA vaccination under …
SARS-CoV-2 vaccination; most NH residents received BNT162b2 mRNA vaccination under …
Determining the Time of Booster Dose Based on the Half-Life and Neutralization Titers against SARS-CoV-2 Variants of Concern in Fully Vaccinated Individuals
YC Dai, YC Lin, LL Ching, JJ Tsai… - Microbiology …, 2023 - Am Soc Microbiol
Although mRNA-based COVID-19 vaccines reduce the risk of severe disease,
hospitalization and death, vaccine effectiveness (VE) against infection and disease from …
hospitalization and death, vaccine effectiveness (VE) against infection and disease from …
Poor antibody response to BioNTech/Pfizer COVID-19 vaccination in SARS-CoV-2 naïve residents of nursing homes
P Pannus, KY Neven, S De Craeye, L Heyndrickx… - medRxiv, 2021 - medrxiv.org
Background Residents of nursing homes (NH) are at high risk of COVID-19 related morbidity
and death and may respond poorly to vaccination because of old age and frequent …
and death and may respond poorly to vaccination because of old age and frequent …
[HTML][HTML] Vaccine effectiveness against symptomatic SARS-CoV-2 infection in adults aged 65 years and older in primary care: I-MOVE-COVID-19 project, Europe …
E Kissling, M Hooiveld, VS Martín… - …, 2021 - eurosurveillance.org
We measured COVID-19 vaccine effectiveness (VE) against symptomatic SARS-CoV-2
infection at primary care/outpatient level among adults≥ 65 years old using a multicentre …
infection at primary care/outpatient level among adults≥ 65 years old using a multicentre …
Reduced antibody acquisition with increasing age following vaccination with BNT162b2: results from two longitudinal cohort studies in the Netherlands
LL van den Hoogen, M Boer, A Postema, L de Rond… - Vaccines, 2022 - mdpi.com
Vaccine-induced protection against severe COVID-19, hospitalization, and death is of the
utmost importance, especially in the elderly. However, limited data are available on humoral …
utmost importance, especially in the elderly. However, limited data are available on humoral …
COVID-19 vaccine booster dose needed to achieve Omicron-specific neutralisation in nursing home residents
Background Nursing home (NH) residents have borne a disproportionate share of SARS-
CoV-2 morbidity and mortality. Vaccines have limited hospitalisation and death from earlier …
CoV-2 morbidity and mortality. Vaccines have limited hospitalisation and death from earlier …
Effectiveness of BNT162b2 and ChAdOx1 nCoV-19 COVID-19 vaccination at preventing hospitalisations in people aged at least 80 years: a test-negative, case …
Summary Background On Dec 8, 2020, deployment of the first SARS-CoV-2 vaccination
authorised for UK use (BNT162b2 mRNA vaccine) began, followed by an adenoviral vector …
authorised for UK use (BNT162b2 mRNA vaccine) began, followed by an adenoviral vector …
[HTML][HTML] Vaccine effectiveness and duration of protection against symptomatic infections and severe Covid-19 outcomes in adults aged 50 years and over, France …
MS Castillo, H Khaoua, N Courtejoie - Global Epidemiology, 2022 - Elsevier
Background SARS-CoV-2 continues to spread despite fast vaccine rollout, which could be
attributed to waning immunity or to a reduced protection against some variants. A thorough …
attributed to waning immunity or to a reduced protection against some variants. A thorough …
Humoral and cellular responses to COVID-19 vaccination indicate the need for post-vaccination testing in frail population
W Witkowski, S Gerlo, E De Smet, M Wejda, D Acar… - Vaccines, 2022 - mdpi.com
Despite the high efficacy of the BNT162b2 vaccine in the general population, data on its
immunogenicity among frail elderly individuals are limited. Recently, levels of anti-SARS …
immunogenicity among frail elderly individuals are limited. Recently, levels of anti-SARS …